



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN NEUROLOGY

Beginning in 2017, the American Board of Psychiatry and Neurology, Inc. (ABPN) issued two-dimensional content specifications for the psychiatry, neurology and child neurology certification examinations. Questions for the September 2021 psychiatry, neurology and child neurology certification examinations will conform to these content specifications.

Within the two-dimensional format, one dimension is comprised of disorders and topics while the other is comprised of competencies and mechanisms that cut across the various disorders of the first dimension. By design, the two dimensions are interrelated and not independent of each other. All of the questions on the examination will fall into one of the disorders/topics and will be aligned with a competency/mechanism. For example, an item on substance use could focus on treatment, or it could focus on systems-based practice.

The psychiatry, neurology and child neurology content specifications can be accessed from the [specialty certification section](#) of our website.

Candidates should use the detailed content specifications as a guide to prepare for a certification examination. Scores for these examinations will be reported in a standardized format rather than the previous percent correct format.

Starting in 2018, all future examinations given by the ABPN will gradually conform to the two-dimensional content specification.

The American Board of Psychiatry and Neurology, Inc. is a not-for-profit corporation dedicated to serving the public interest and the professions of psychiatry and neurology by promoting excellence in practice through certification and maintenance of certification processes.

For more information, please contact us at questions@abpn.com or visit our website at www.abpn.com.



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN NEUROLOGY 2021 Content Blueprint

| | | |
|--|--|-------|
| Number of questions: 400 | | |
| Dimension 1 | | |
| Neurologic Disorders and Topics | | |
| 01. | Headache and pain disorders | 4-6% |
| 02. | Epilepsy and episodic disorders | 8-12% |
| 03. | Sleep disorders | 3-5% |
| 04. | Genetic and developmental disorders | 6-8% |
| 05. | Vascular neurology | 8-12% |
| 06. | Neuromuscular diseases | 9-13% |
| 07. | Movement disorders | 8-12% |
| 08. | Demyelinating diseases | 7-11% |
| 09. | Neuroinfectious diseases | 2-4% |
| 10. | Brain and spinal trauma and spinal diseases | 2-4% |
| 11. | Neuro-ophthalmologic and neuro-otologic disorders | 2-4% |
| 12. | Metabolic diseases, nutritional deficiency states, and disorders due to toxins, drugs, and physical agents | 3-5% |
| 13. | Neuro-oncologic disorders | 1-3% |
| 14. | Behavioral neurology and neurocognitive disorders | 7-9% |
| 15. | Psychiatric disorders | 5-7% |
| 16. | Autonomic nervous system disorders | 1-2% |
| 17. | Questions not associated with a specific neurologic disorder | 1-3% |
| 18. | Neuroimmunologic and paraneoplastic CNS disorders | 1-3% |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN NEUROLOGY 2021 Content Blueprint

| | | |
|--|---|--------|
| Number of questions: 400 | | |
| Dimension 2 | | |
| Physician Competencies and Mechanisms | | |
| A. | Neuroscience and mechanism of disease | 22-28% |
| B. | Clinical aspects of neurologic disease | 17-23% |
| C. | Diagnostic procedures | 17-23% |
| D. | Treatment/Management | 22-28% |
| E. | Interpersonal and communication skills | 2-3% |
| F. | Professionalism | 2-3% |
| G. | Practice-based learning and improvement | 2-3% |
| H. | Systems-based practice | 2-3% |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

CERTIFICATION EXAMINATION IN NEUROLOGY 2021 Content Outline

| |
|---|
| Number of items: 400 (350 scored, 50 pretest) |
| Dimension 1 |
| Neurologic Disorders and Topics |
| 01. Headache and pain disorders |
| A. Headache |
| 01. Primary headaches |
| a. Migraine |
| b. Tension-type headache |
| c. Cluster headache and other trigeminal autonomic cephalalgias |
| d. Other primary headaches (exertional headache, etc.) |
| 02. Secondary headaches |
| a. Headache due to head and neck trauma (posttraumatic headache) |
| b. Headache due to cranial or cervical vascular disorder (thunderclap headache, reversible cerebral vasoconstriction syndrome (RCVS), arterial dissection, cerebral hemorrhage, ischemia) |
| c. Headache due to nonvascular intracranial disorder (hydrocephalus, idiopathic intracranial hypertension, low-CSF-pressure headaches, tumors) |
| d. Headache due to infection |
| e. Headache due to a substance or its withdrawal |
| f. Headache or facial pain due to disorder of cranium, neck, eyes, ears, nose, sinuses, and teeth |
| g. Headache due to psychiatric disorder |
| 03. Cranial neuralgia, central and primary facial pain (trigeminal neuralgia, idiopathic facial pain, post-herpetic neuralgia) |
| B. Pain disorders |
| 01. Central pain syndromes (thalamic, phantom, etc.) |
| 02. Complex regional pain syndromes |
| 02. Epilepsy and episodic disorders |
| A. Generalized seizures |
| 01. Tonic-clonic |
| 02. Absence |
| a. Typical |
| b. Atypical |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| c. Absence with special features |
| 03. Myoclonic |
| 04. Clonic |
| 05. Tonic |
| 06. Atonic |
| B. Focal seizures |
| 01. Simple partial |
| 02. Complex partial |
| 03. Focal evolving to bilateral convulsive seizure |
| C. Electro-clinical syndromes |
| 01. Neonatal period |
| a. Benign familial neonatal seizures (BFNS) |
| b. Early myoclonic encephalopathy (EME) |
| c. Ohtohara syndrome |
| 02. Infancy |
| a. West syndrome |
| b. Myoclonic epilepsy in infancy |
| c. Benign infantile seizures |
| d. Benign familial infantile seizures |
| e. Dravet syndrome |
| f. Myoclonic encephalopathy in nonprogressive disorders |
| 03. Childhood |
| a. Febrile seizures (FS+) |
| b. Early benign childhood occipital epilepsy (Panayiotopoulos type) |
| c. Epilepsy with myoclonic-atonic seizures |
| d. Benign epilepsy with centrotemporal spikes (BECTS) |
| e. Autosomal dominant nocturnal frontal lobe epilepsy (ADNFLE) |
| f. Late-onset childhood occipital epilepsy (Gastaut type) |
| g. Epilepsy with myoclonic absences |
| h. Lennox-Gastaut syndrome |
| i. Epileptic encephalopathy with continuous spike-and-wave during sleep (CSWS) including Landau-Kleffner syndrome |
| j. Childhood absence epilepsy |
| 04. Adolescence through adult |
| a. Juvenile absence epilepsy (JAE) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| b. Juvenile myoclonic epilepsy (JME) |
| c. Epilepsy with generalized tonic-clonic seizures alone |
| d. Progressive myoclonic epilepsies (PME) |
| e. Autosomal dominant partial epilepsy with auditory features (ADPEAF) |
| f. Other familial temporal lobe epilepsies |
| D. Less specific age relationship |
| 01. Familial focal epilepsy with variable foci |
| 02. Reflex epilepsies |
| E. Distinctive constellations |
| 01. Mesial temporal lobe epilepsy with hippocampal sclerosis (MTLE with HS) |
| 02. Rasmussen syndrome |
| 03. Gelastic seizures with hypothalamic hamartoma |
| F. Epilepsies attributed to and organized by structural-metabolic causes |
| 01. Structural, including tumors in vascular malformations |
| 02. Infection |
| 03. Trauma |
| 04. Perinatal insults |
| 05. Malformations of cortical development, including neurocutaneous syndromes |
| 06. Mitochondrial and metabolic disorders |
| G. Epilepsies of unknown cause |
| H. Conditions with epileptic seizures traditionally not diagnosed as a form of epilepsy |
| 01. Benign neonatal seizures (BNS) |
| 02. Febrile seizures (FS) |
| I. Non-epileptic paroxysmal disorders |
| 01. Breath-holding spells |
| 02. Cardiac etiologies (e.g., prolonged QT interval) |
| 03. Syncope, convulsive and nonconvulsive |
| 04. Gastroesophageal reflux and Sandifer syndrome |
| 05. Gratification phenomena and masturbation |
| 06. Shuddering/shivering |
| 07. Acute confusional migraine |
| 08. Benign infant myoclonus |
| 09. Psychogenic non-epileptic seizures |
| J. Status epilepticus |
| 01. Convulsive |
| 02. Non-convulsive |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 03. Sleep disorders |
| A. Insomnia |
| 01. Psychological insomnia |
| 02. Inadequate sleep hygiene |
| B. Sleep-disordered breathing |
| 01. Obstructive sleep apnea |
| 02. Central apnea syndromes |
| 03. Sleep-related hypoventilation disorders |
| C. Central disorders of hypersomnolence |
| 01. Narcolepsy (with and without cataplexy) |
| 02. Kleine-Levin syndrome |
| 03. Hypersomnia due to a medical condition |
| 04. Insufficient sleep syndrome |
| D. Circadian rhythm sleep-wake disorders |
| 01. Delayed sleep-wake phase disorder |
| 02. Advanced sleep-wake phase disorder |
| 03. Irregular sleep-wake rhythm disorder |
| 04. Non-24-hour sleep-wake phase disorder |
| E. Parasomnias |
| 01. NREM-related parasomnias |
| a. Arousal disorders, including sleepwalking, sleep terrors, and confusional arousals |
| i. Sleepwalking |
| ii. Sleep terrors |
| iii. Confusional arousals |
| b. Sleep-related eating disorder |
| 02. REM-related parasomnias |
| a. REM sleep behavior disorder |
| b. Recurrent isolated sleep paralysis |
| c. Nightmare disorder |
| 03. Other |
| a. Exploding head syndrome |
| b. Sleep-related hallucinations |
| c. Sleep enuresis |
| d. Parasomnia due to a general medical disorder |
| e. Medication/substance-related parasomnia |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| f. Unspecified parasomnia |
| F. Sleep-related movement disorders |
| 01. Periodic limb movements of sleep |
| 02. Sleep-related limb cramps |
| 03. Sleep-related bruxism |
| 04. Benign myoclonus of infancy |
| G. Sleep disorders in other conditions |
| 01. Sleep disturbances in movement conditions |
| a. Parkinson disease |
| b. Multisystem atrophy |
| c. Dementia with Lewy bodies |
| d. Spinocerebellar degeneration |
| e. Huntington disease |
| 02. Amyotrophic lateral sclerosis |
| 03. Alzheimer disease |
| 04. Effects of sleep disorders on cardiovascular/cerebrovascular risk factors |
| a. Hypertension |
| b. Atrial fibrillation |
| c. Congestive heart failure |
| d. Myocardial infarction |
| e. Stroke |
| 04. Genetic and developmental disorders |
| A. Inherited metabolic disorders |
| 01. Disorders of amino acid metabolism |
| a. Phenylketonuria |
| b. Nonketotic hyperglycemia |
| c. Other |
| 02. Disorders of urea cycle metabolism |
| a. Ornithine transcarbamylase |
| b. Other |
| 03. Disorders of sulfur amino acids |
| a. Homocystinuria |
| b. Other |
| 04. Disorders of amino acid transport |
| a. Hartnup disease |
| b. Lowe syndrome |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| c. Other |
| 05. Disorders of carbohydrate metabolism and transport |
| a. Galactosemia |
| b. Glucose transporter deficiency |
| c. Other |
| 06. Organic acidurias |
| a. Methylmalonic acidurias |
| b. Glutaric acidurias |
| c. Other |
| 07. Disorders of fatty acid oxidation |
| 08. Disorders of purine metabolism |
| a. Lesch-Nyhan syndrome |
| b. Other |
| 09. Porphyria |
| 10. Other |
| B. Lysosomal disorders |
| 01. Glycogen storage diseases |
| a. Pompe disease |
| b. Mucopolysaccharidoses |
| c. Other |
| 02. Gangliosidoses |
| a. Tay-Sachs disease |
| b. Other |
| 03. Gaucher disease |
| 04. Fabry disease |
| 05. Niemann-Pick disease |
| 06. Neuronal ceroid and lipofuscinosis |
| 07. Other |
| C. Leukodystrophies |
| 01. Adrenoleukodystrophy |
| 02. Pelizaeus-Merzbacher disease |
| 03. Canavan disease |
| 04. Alexander disease |
| 05. Metachromatic leukodystrophy |
| 06. Krabbe disease |
| 07. Other |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| D. Additional disorders |
| 01. Rett syndrome |
| 02. Mitochondrial disorders |
| 03. Peroxisomal disorders |
| 04. Other |
| E. Chromosomal disorders |
| 01. Autosomal abnormalities |
| a. Down syndrome (trisomy 21) |
| b. Trisomy 13 |
| c. Cri du chat syndrome |
| d. Duplication/deletion |
| e. Williams syndrome |
| f. Other |
| 02. X-chromosomal disorders |
| a. Fragile X syndrome |
| b. Other |
| 03. Other |
| F. Disorders of brain and spine development |
| 01. Anencephaly |
| 02. Myelomeningocele and encephalocele |
| 03. Chiari malformations |
| 04. Other cord dysraphism |
| a. Syringomyelia |
| b. Diastematomyelia |
| 05. Cerebellar malformations |
| 06. Skull malformations, including craniosynostosis |
| a. Goubert syndrome |
| b. Dandy Walker and variants |
| c. Other |
| 07. Brain malformations |
| a. Holoprosencephaly |
| b. Septo-optic dysplasia |
| c. Schizencephaly |
| d. Lissencephaly and other migrational abnormalities |
| e. Agenesis of the corpus callosum |
| f. Hemimegalencephaly |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 08. Microencephaly and micrencephaly |
| 09. Macrencephaly, megalencephaly, and other overgrowth syndromes |
| 10. Hydrocephalus |
| 11. Cystic malformations (arachnoid, colloid, pineal, dermoid) |
| G. Neurocutaneous syndromes |
| 01. Neurofibromatosis 1 and 2 |
| 02. Tuberous sclerosis |
| 03. Sturge-Weber syndrome |
| 04. Ataxia-telangiectasia |
| 05. Von Hippel-Lindau disease |
| 06. Incontinentia pigmenti |
| 07. Other |
| H. Cerebral palsy |
| 01. Spastic |
| 02. Dyskinetic/dystonic |
| 03. Ataxic |
| 04. Other |
| 05. Vascular neurology |
| A. Ischemic stroke (cerebral infarction and transient ischemic attack) |
| 01. Atherosclerosis |
| a. Large-artery |
| b. Small-artery |
| 02. Cardioembolic |
| 03. Arterial dissection |
| 04. Other vasculopathies, including hypercoagulability (thrombophilia) and vasculitis |
| 05. Spinal cord infarction/ischemia |
| 06. Other |
| B. Intracerebral hemorrhage |
| 01. Chronic hypertension |
| 02. Vascular malformations |
| 03. Bleeding diatheses and antithrombotic agents |
| 04. Amyloid angiopathy |
| 05. Tumors |
| 06. Pituitary apoplexy |
| 07. Other |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| C. Subarachnoid hemorrhage |
| 01. Aneurysm |
| 02. Vascular malformations |
| 03. Complications (including vasospasm) |
| D. Cerebral venous thrombosis |
| 01. Pregnancy and puerperium |
| 02. Hypercoagulability (thrombophilia) |
| E. Cerebrovascular constriction, including reversible cerebrovascular constriction syndrome and posterior reversible encephalopathy syndrome (PRES) |
| F. Sickle cell disease |
| G. Unruptured aneurysm and vascular malformation |
| H. CADASIL |
| I. Other |
| 06. Neuromuscular diseases |
| A. Motor neuron disorders |
| 01. Amyotrophic lateral sclerosis (sporadic) |
| 02. Genetic |
| a. Familial amyotrophic lateral sclerosis |
| b. Spinal muscular atrophy |
| c. Kennedy disease |
| d. Tay-Sachs disease |
| 03. Focal, including Hirayama disease |
| 04. Paraneoplastic |
| B. Spinal root disorders |
| 01. Cervical |
| 02. Thoracic |
| 03. Lumbosacral |
| 04. Polyradiculopathy |
| 05. Specific etiologies |
| a. Diabetes |
| b. Segmental herpes zoster and post-herpetic neuralgia |
| C. Plexopathies |
| 01. Brachial |
| a. Traumatic (neonatal, penetrating injury) |
| b. Radiation-induced |
| c. Neuralgic amyotrophy (brachial neuritis) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| d. Hereditary neuralgic amyotrophy |
| e. Neoplastic |
| 02. Lumbosacral |
| a. Traumatic (hematoma, ischemic) |
| b. Radiation-induced |
| c. Diabetic radiculo-plexo-neuropathy |
| d. Neoplastic |
| D. Peripheral nerve disorders |
| 01. Mononeuropathies |
| a. Median |
| b. Ulnar |
| c. Radial |
| d. Musculocutaneous |
| e. Axillary |
| f. Spinal accessory |
| g. Suprascapular |
| h. Sciatic |
| i. Peroneal (fibular) |
| j. Tibial |
| k. Femoral |
| l. Obturator |
| m. Facial |
| n. Trigeminal |
| o. Lateral femoral cutaneous (meralgia paresthetica) |
| p. Other |
| 02. Mononeuropathy multiplex |
| a. Diabetic |
| b. Vasculitic |
| 03. Polyneuropathy |
| a. Hereditary |
| i. Demyelinating |
| (a) CMT1a |
| (b) CMTX |
| (c) Hereditary neuropathy with tendencies to pressure palsy (HNPP) |
| (d) Refsum disease |
| ii. Axon loss (CMT2) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| iii. TTR amyloid polyneuropathy |
| b. Acquired |
| i. Demyelinating |
| (a) Acute inflammatory demyelinating polyneuropathy (AIDP) |
| (i) Guillain-Barré syndrome |
| (ii) Miller Fisher variant (GQ1b antibody) |
| (iii) Acute motor axonal neuropathy (AMAN) |
| (iv) Acute motor and sensory axonal neuropathy (AMSAN) |
| (b) Chronic inflammatory demyelinating polyneuropathy (CIDP) |
| (c) Multifocal mononeuropathy with conduction block |
| ii. Metabolic |
| (a) Diabetic |
| (b) Nutritional |
| (i) Vitamin B ₆ deficiency |
| (ii) Vitamin B ₁₂ deficiency |
| (iii) Copper deficiency |
| (iv) Alcohol |
| (v) Hypervitaminosis B ₆ |
| iii. Toxic |
| (a) Arsenic, lead, thallium |
| (b) n-Hexane |
| (c) Organophosphates |
| (d) Drug-induced |
| (i) Isoniazide |
| (ii) Metronidazole |
| (iii) Nitrofurantoin |
| (iv) Chloroquine/hydroxychloroquine |
| (v) Lithium |
| (vi) Other |
| (e) Other |
| iv. Immune/inflammatory |
| (a) Paraneoplastic |
| (b) Amyloidosis |
| (c) Sarcoidosis |
| (d) Paraproteinemic |
| v. Small-fiber sensory polyneuropathy |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| c. Dorsal root ganglion disorders |
| i. Nutritional/toxic, including hypervitaminosis B ₆ |
| ii. Autoimmune/inflammatory |
| (a) Hu antibody syndrome |
| (b) Connective tissue disease (Sjogren syndrome) |
| iii. Friedreich ataxia |
| E. Neuromuscular junction transmission disorders |
| 01. Myasthenia gravis |
| 02. Lambert-Eaton myasthenic syndrome |
| 03. Botulism |
| 04. Congenital/hereditary myasthenia |
| F. Muscle disorders |
| 01. Muscular dystrophies |
| a. Duchenne/Becker |
| b. Facioscapulohumeral |
| c. Limb-girdle |
| i. Calpain LGMD 2A |
| ii. Dysferlin LGMD 2B (including distal presentation) |
| iii. Sarcoglycan LGMD 2C-F |
| iv. FKRP LGMD 2I |
| d. Myotonic |
| i. Myotonic dystrophy 1 (including distal presentation) |
| ii. Myotonic dystrophy 2 |
| e. Oculopharyngeal |
| f. Myofibrillar (including distal presentation) |
| g. Congenital muscular dystrophy |
| 02. Congenital myopathies |
| a. Central core |
| b. Nemaline |
| c. Centronuclear/myotubular (including distal presentation) |
| 03. Metabolic myopathies |
| a. Mitochondrial |
| i. Myoclonic epilepsy with ragged red fibers (MERRF) |
| ii. Mitochondrial myopathy, lactic acid, and stroke (MELAS) |
| iii. Kearns-Sayre syndrome |
| iv. Other |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| b. Glycogenoses |
| i. Pompe disease |
| ii. Myophosphorylase deficiency (McArdle disease) |
| c. Lipidoses |
| i. Carnitine deficiency |
| ii. Carnitine palmitoyltransferase 2 deficiency (CPT2) |
| d. Periodic paralyses |
| i. Hypokalemic |
| ii. Hyperkalemic |
| 04. Acquired myopathies |
| a. Inflammatory myopathies |
| i. Polymyositis |
| ii. Dermatomyositis |
| iii. Inclusion body myositis |
| (a) Sporadic (including distal presentation) |
| (b) Hereditary (including distal presentation) |
| iv. Sarcoidosis |
| v. HIV |
| b. Critical illness myopathy |
| c. Toxic/drug-induced myopathy |
| i. HMG-CoA reductase |
| ii. Alcohol |
| iii. Chloroquine/hydroxychloroquine |
| iv. Corticosteroids |
| v. Colchicine |
| d. Metabolic/endocrine |
| i. Hypothyroid |
| ii. Hyperthyroid |
| iii. Hypokalemic |
| 05. Rhabdomyolysis |
| G. Hyper-excitability disorders |
| 01. Stiff-person syndromes |
| 02. Potassium channelopathies (Isaac syndrome) |
| H. Autonomic dysfunction in neuromuscular diseases |
| 01. Autoimmune autonomic neuropathy and ganglionopathy (including Sjogren syndrome) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 02. Guillain Barre syndrome (autonomic manifestations) |
| 03. Paraneoplastic autonomic neuropathies |
| 04. Fabry disease |
| 05. Autonomic neuropathies due to infectious disease |
| a. Chagas disease |
| b. Leprosy |
| c. Diphtheria |
| 06. Diabetes (autonomic manifestations) |
| 07. Amyloidosis |
| 08. Adie syndrome |
| 09. Small fiber polyneuropathy (autonomic manifestations) |
| 10. Toxic neuropathies |
| a. Vacor |
| b. Hexane |
| c. Ciguatoxin |
| d. Vincristine |
| e. Cisplatin, paclitaxel |
| f. Heavy metals (arsenic, mercury, thallium) |
| g. Other |
| 11. Other |
| 07. Movement disorders |
| A. Parkinson disease and parkinsonism |
| 01. Neurodegenerative |
| a. Idiopathic Parkinson disease (including diffuse Lewy body disease and dementia with Lewy body) |
| b. Multiple system atrophy |
| c. Progressive supranuclear palsy |
| d. Corticobasal degeneration |
| 02. Post-traumatic parkinsonism |
| 03. Vascular parkinsonism |
| 04. Drug-induced parkinsonism |
| 05. Hydrocephalus and normal-pressure hydrocephalus |
| 06. Juvenile parkinsonism |
| B. Tremor |
| 01. Essential tremor |
| 02. Physiological tremor |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 03. Drug-induced tremor |
| C. Chorea |
| 01. Huntington disease |
| 02. Sydenham chorea |
| 03. Drug-induced chorea |
| 04. Chorea gravidarum |
| 05. Neuroacanthocytosis |
| D. Ballism and athetosis |
| E. Dystonia |
| 01. Focal dystonia |
| a. Genetic |
| b. Non-genetic |
| 02. Generalized dystonia |
| a. Genetic |
| b. Non-genetic |
| 03. Dopa-responsive dystonia |
| 04. Other |
| F. Wilson disease |
| G. Neuroleptic-induced syndromes, acute and chronic |
| 01. Acute dystonic reaction |
| 02. Tardive syndromes |
| a. Tardive dyskinesia |
| b. Tardive dystonia |
| c. Tardive akathisia |
| H. Tic disorders |
| 01. Tourette syndrome |
| 02. Other |
| I. Myoclonus |
| 01. Essential myoclonus |
| 02. Post-hypoxic myoclonus |
| J. Other paroxysmal disorders |
| 01. Hemifacial spasm |
| 02. Dyskinesias |
| 03. Restless legs syndrome |
| 04. Automatism |
| K. Ataxia |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| 01. Spinocerebellar ataxias |
| 02. Friedreich ataxia |
| 03. Vitamin |
| 04. Paroxysmal ataxia |
| L. Psychogenic movement disorders |
| 01. Psychogenic tremor |
| 02. Psychogenic dystonia |
| 03. Psychogenic gait disturbance and ataxia |
| M. Critical care |
| 01. Acute parkinsonism |
| 02. Neuroleptic malignant syndrome |
| 03. Serotonin syndrome |
| 04. Dystonic storm |
| 05. Ballism |
| 06. Tic status |
| 08. Demyelinating diseases |
| A. Multiple sclerosis and variants |
| B. Neuromyelitis optica |
| C. Acute disseminated encephalomyelitis and variants |
| D. Transverse myelitis |
| E. Other |
| 09. Neuroinfectious diseases |
| A. Bacterial infections |
| 01. Meningitis |
| a. Neonatal |
| i. E. coli |
| ii. Streptococcus |
| iii. Listeria |
| iiii. Other |
| b. Childhood |
| i. Hemophilus influenza |
| ii. Streptococcus pneumonia |
| iii. Other |
| c. Adolescent |
| i. Neisseria meningitis |
| ii. Other |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| d. Adult |
| i. Streptococcus pneumonia |
| ii. Listeria |
| iii. Other |
| 02. Brain and spine abscess |
| B. Fungal infections |
| 01. Meningitis |
| a. Cryptococcus |
| b. Histoplasmosis |
| c. Coccidiomycosis |
| d. Other |
| 02. Cerebritis |
| a. Aspergillosis |
| b. Phycomycosis |
| c. Other |
| C. Mycobacteria, including tuberculosis |
| D. Viral infections |
| 01. Meningitis |
| 02. Encephalitis and myelitis |
| a. West Nile |
| b. Herpes simplex |
| c. Herpes zoster |
| d. Arbovirus |
| e. Rabies |
| f. HIV |
| g. Progressive multifocal leukoencephalopathy |
| h. Polio |
| i. Acute flaccid paralysis/Polio-like syndrome |
| i. Cytomegalovirus |
| j. Measles |
| k. Other |
| E. Protozoan infections |
| 01. Toxoplasmosis |
| 02. Naegleria |
| 03. Trypanosomiasis |
| 04. Other |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| F. Parasitic infections |
| 01. Cysticercosis |
| 02. Other |
| G. Prion infections |
| H. Non-infectious causes of meningitis |
| I. Systemic infections with neurologic effects |
| 01. Lyme disease |
| 02. Syphilis |
| 03. Diphtheria |
| 04. Tetanus |
| 05. Whipple disease |
| 06. Leprosy |
| 07. Other |
| 10. Brain and spinal trauma and spinal diseases |
| A. Brain trauma |
| 01. Cerebral concussion, including chronic traumatic encephalopathy |
| 02. Diffuse axonal injury |
| 03. Cerebral contusion |
| 04. Traumatic hemorrhage |
| a. Epidural hematoma |
| b. Subdural hematoma |
| c. Traumatic subarachnoid hemorrhage |
| B. Spinal trauma |
| 01. Spinal cord contusion and transection |
| 02. Spinal epidural hematoma |
| C. Non-traumatic spinal disorders |
| 01. Spinal cord or cauda equina compression from disc or bone |
| 02. Spinal cord herniation |
| 03. Associated autonomic disorders |
| 04. Other |
| D. Non-accidental trauma in children |
| 11. Neuro-ophthalmologic and neuro-otologic disorders |
| A. Neuro-ophthalmology |
| 01. Disorders of the optic nerve |
| a. Vascular (e.g., anterior ischemic optic neuropathy) |
| b. Inflammatory (e.g., optic neuritis) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| c. Toxic and nutritional optic nerve disease |
| d. Inherited (e.g., Leber optic atrophy) |
| e. Papilledema and pseudopapilledema |
| f. Optic nerve tumor |
| 02. Disorders of the retina |
| a. Retinal artery occlusion, including Susac syndrome |
| b. Retinal venous occlusion |
| c. Retinal degenerations |
| d. Phakomatoses |
| 03. Other lesions of optic pathways |
| a. Optic chiasm |
| b. Optic tracts |
| c. Optic radiations |
| d. Visual cortex, including visual agnosias and cortical blindness |
| 04. Disorders of the pupil |
| a. Horner syndrome |
| b. Argyll-Robertson pupil |
| c. Tonic pupil |
| 05. Disorders of ocular motility |
| a. Disorders of supranuclear control of eye movements |
| i. Horizontal gaze paresis, including internuclear ophthalmoplegia (INO) and one-and-a-half syndrome |
| ii. Upgaze paresis, including Parinaud syndrome |
| iii. Downgaze paresis |
| b. Disorders of cranial nerves 3,4, 6, and their nuclei |
| c. Nystagmus |
| B. Neuro-otology |
| 01. Vestibular disease |
| a. Benign positional vertigo |
| b. Ménière disease |
| c. Acute labyrinthitis |
| d. Toxic vestibulopathy |
| e. Cerebellopontine angle tumors |
| f. Central vertigo, including disembarkment syndrome |
| 02. Deafness, including inherited and acquired |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| 03. Other, including pulsatile tinnitus |
| 12. Metabolic diseases, nutritional deficiency states, and disorders due to toxins, drugs, and physical agents |
| A. Metabolic diseases |
| 01. Hypoxic-ischemic encephalopathy |
| 02. Disorders of glucose metabolism, including hypoglycemia, diabetic ketoacidosis, and nonketotic hyperglycemia |
| 03. Hepatic encephalopathy |
| 04. Uremic encephalopathy, including dialysis dementia and dialysis dysequilibrium syndrome |
| 05. Disorders of sodium, potassium, and water metabolism, including hyponatremia, hypernatremia, hypokalemia, and hyperkalemia |
| 06. Disorders of calcium and magnesium metabolism, including hypocalcemia, hypercalcemia, hypomagnesemia, and hypermagnesemia |
| 07. Endocrine diseases, including those of thyroid, parathyroid, adrenal, and pituitary glands (including pituitary apoplexy) |
| 08. Drug overdose |
| B. Nutritional deficiency states |
| 01. B vitamins |
| a. Thiamine (including Wernicke encephalopathy) |
| b. Niacin |
| c. Pyridoxine |
| d. Cobalamin |
| e. Folic acid |
| 02. Vitamin E |
| 03. Vitamins A and D |
| 04. Other |
| a. Copper deficiency |
| b. Protein calorie malnutrition |
| c. Strachan syndrome and related disorders |
| d. Complications of bariatric surgery |
| C. Toxins, drugs, and physical agents |
| 01. Exposure to chemicals |
| a. Acrylamide |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| b. Carbon disulfide |
| c. Ethylene oxide |
| d. Hexacarbon solvents |
| e. Organophosphates |
| f. Toluene |
| g. Other |
| 02. Exposure to metals |
| a. Aluminum |
| b. Arsenic |
| c. Lead |
| d. Manganese |
| e. Mercury |
| f. Thallium |
| g. Tin |
| h. Other |
| 03. Effects of drug abuse |
| a. Opioids |
| b. Cocaine |
| c. Amphetamines |
| d. Sedative-hypnotics |
| e. Inhalants |
| f. Hallucinogens |
| g. Other |
| 04. Effects of alcohol |
| a. Acute alcoholic intoxication |
| b. Alcohol withdrawal syndromes |
| c. Effects related to nutritional deficiency |
| d. Effects of unknown etiology (e.g., Marchiafava-Bignami disease) |
| e. Effects of alcohols other than ethanol (e.g., methyl alcohol and ethylene glycol) |
| 05. Effects of ionizing radiation |
| a. Encephalopathy |
| b. Myelopathy |
| c. Plexopathy |
| 06. Hypothermia and hyperthermia |
| 07. Electric current and lightning |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| 08. Animal and insect neurotoxins |
| a. Snakes |
| b. Spiders |
| c. Scorpions |
| d. Tick paralysis |
| 09. Marine neurotoxins |
| a. Ciguatera fish poisoning |
| b. Puffer fish poisoning |
| 10. Plant neurotoxins |
| a. Mushroom poisoning |
| b. Other |
| D. Iatrogenic/therapeutic drugs |
| 13. Neuro-oncologic disorders |
| A. Neoplasms |
| 01. Primary |
| a. Primitive neuroectodermal tumors |
| i. Medulloblastoma |
| ii. Retinoblastoma |
| b. Gliomas |
| i. Astrocytoma |
| (a) Low-grade |
| (i) Pilocytic astrocytoma |
| (ii) Astrocytoma |
| (b) High-grade |
| (i) Anaplastic astrocytoma |
| (ii) Glioblastoma |
| ii. Oligodendroglioma |
| (a) Oligodendroglioma |
| (b) Anaplastic oligodendroglioma |
| iii. Ependymoma |
| (a) Ependymoma |
| (b) Anaplastic ependymoma |
| (c) Myxopapillary ependymoma |
| c. Neuronal tumors |
| i. Central neurocytoma |
| ii. Dysembryoblastic neuroectodermal tumor (DNET) |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| iii. Gangliocytoma |
| iv. Ganglioglioma |
| d. Meningioma |
| e. Nerve sheath tumors |
| i. Schwannoma |
| ii. Neurofibroma |
| f. Primary CNS lymphoma |
| g. Craniopharyngioma |
| h. Pituitary adenoma |
| i. Pineal tumors |
| j. Choroid plexus tumors |
| 02. Secondary |
| a. Metastatic intraparenchymal |
| b. Meningeal carcinomatosis |
| c. Metastases to spine and skull |
| B. Hereditary tumor syndromes |
| 01. Neurofibromatosis |
| 02. Von Hippel-Lindau disease |
| 03. Tuberous sclerosis |
| 04. Cowden syndrome |
| 05. Multiple endocrine neoplasms (MEN) |
| C. Non-metastatic neurologic complications of systemic cancer |
| 01. Vascular disease |
| D. Neurologic complications of cancer treatment |
| 01. Radiation therapy |
| a. Radiation necrosis |
| b. Secondary neoplasms |
| 02. Chemotherapy |
| 14. Behavioral neurology and neurocognitive disorders |
| A. Delirium, dementia, and other cognitive disorders |
| 01. Delirium |
| a. Delirium due to a medical condition |
| b. Substance intoxication delirium |
| c. Substance withdrawal delirium |
| d. Delirium due to multiple etiologies |
| e. Other |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| 02. Dementia |
| a. Mild cognitive impairment |
| b. Alzheimer disease |
| c. Vascular dementia |
| d. HIV disease |
| e. Traumatic brain injury |
| f. Frontotemporal disorders |
| g. Dementia due to a medical condition |
| h. Substance/medication-induced dementia |
| i. Multiple etiologies, including metabolic, endocrine, toxic, and neoplastic/paraneoplastic |
| 03. Amnestic disorders (including transient global amnesia) |
| 04. Other |
| B. Neurodevelopmental disorders |
| 01. Learning disorders |
| 02. Communication disorders |
| 03. Autism spectrum disorders |
| 04. Attention-deficit and disruptive behavior disorders |
| 05. Other (global developmental delay/intellectual disability) |
| C. Higher cortical function and clinical syndromes |
| 01. Frontal lobe syndromes |
| 02. Aphasia |
| 03. Apraxia |
| 04. Neglect |
| 05. Agnosia |
| 06. Disconnection syndromes |
| D. Alteration of mental status/encephalopathy/coma/brain death |
| E. Other |
| 15. Psychiatric disorders |
| A. Schizophrenia and other psychotic disorders |
| 01. Schizophrenia |
| 02. Brief psychotic disorder |
| 03. Psychotic disorder due to another medical condition |
| 04. Substance/medication-induced psychotic disorder |
| 05. Other |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| B. Depressive disorders |
| 01. Depressive disorders |
| a. Major depressive disorder |
| b. Persistent depressive disorder (dysthymia) |
| c. Depressive disorder due to another medical condition |
| d. Other |
| C. Bipolar and related disorders |
| 01. Bipolar I disorder |
| 02. Bipolar II disorder |
| D. Anxiety disorders |
| 01. Social anxiety |
| 02. Panic disorder |
| 03. Generalized anxiety disorder |
| 04. Anxiety disorder due to another medical condition |
| 05. Substance/medication-induced anxiety disorder |
| 06. Other |
| E. Obsessive-compulsive and related disorders |
| F. Somatic symptom and related disorders |
| 01. Conversion disorder/functional neurological symptom disorder (DSM-5) |
| 02. Pain disorder |
| 03. Somatic symptom disorder |
| 04. Illness anxiety disorder |
| 05. Factitious disorders |
| 06. Other |
| G. Trauma- and stressor-related disorders |
| 01. Post-traumatic stress disorder |
| 02. Acute stress disorder |
| 03. Adjustment disorder |
| H. Sexual disorders |
| 01. Sexual pain disorders |
| 02. Sexual dysfunction due to a general medical condition |
| 03. Other |
| I. Feeding and eating disorders |
| 01. Anorexia nervosa |
| 02. Bulimia nervosa |
| J. Elimination disorders |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| K. Personality disorders |
| L. Other psychiatric disorders |
| 16. Autonomic nervous system disorders |
| A. Disorders of orthostatic tolerance |
| 01. Orthostatic hypotension |
| 02. Postural tachycardia syndrome (POTS) |
| 03. Neurally mediated syncope |
| a. Central causes (emotional) |
| b. Reflex causes |
| i. Carotid sinus stimulation |
| ii. Micturition, defecation, coughing |
| iii. Hemodynamic stress |
| B. Autonomic dysfunction in CNS disorders |
| 01. Lewy body disorders |
| 02. Multiple system atrophy |
| 03. Tauopathies |
| 04. Pure autonomic failure |
| 05. Multiple sclerosis |
| 06. Stroke |
| C. Disorders of sweating and thermoregulation |
| 01. Hypothermia |
| 02. Hyperthermia |
| 03. Regional hyperhidrosis |
| 04. Hypohidrosis (central and peripheral causes) |
| D. Autonomic disorders of the urogenital system |
| 01. Multiple sclerosis |
| 02. Multiple system atrophy |
| E. Autonomic disorders of the gastrointestinal tract |
| 01. Achalasia |
| 02. Gastroparesis |
| 03. Cyclic vomiting syndrome |
| 04. Intestinal pseudo-obstruction |
| 05. Hirschprung disease |
| F. Visceral sensory disorders |
| 01. Disorders of parasympathetic visceral sensation |
| a. Disorders of taste |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| b. Associated with glossopharyngeal neuralgia |
| 02. Disorders of sympathetic visceral sensation: sympathetic storm in spinal cord transection |
| 03. Disorders of central visceral sensation: insular cortex stroke |
| 17. Questions not associated with a specific neurologic disorder |
| A. Normal anatomy, process, neurophysiology |
| B. Pharmacology |
| C. Medical-legal, public policy/regulatory factors, professional practice |
| D. Development through the life cycle: developmental processes, tasks, crises, transitions |
| 01. Childhood (school entry, peer relations, individuation) |
| 02. Adulthood (employment, parenting, acquisition/loss of specific capacities) |
| 03. Late life (cognition, physical endurance, loss of specific capacities) |
| E. Medical, legal, public policy, and professional practice |
| 18. Neuroimmunologic and paraneoplastic CNS disorders |
| A. CNS vasculitis and microangiopathies |
| 01. Primary angiitis of the CNS |
| 02. Secondary CNS vasculitis |
| a. Systemic vasculitides (giant cell arteritis, polyarteritis nodosa, microscopic polyangiitis, Behcet disease) |
| b. Systemic autoimmune disease (systemic lupus erythematosus, rheumatoid arthritis, Sjogren syndrome, sarcoidosis) |
| c. Infectious vasculitis (varicella zoster) |
| d. Substance-induced vasculitis (amphetamines, cocaine) |
| 03. Microangiopathies (Susac syndrome, Sneddon syndrome) |
| B. Neuroimmunologic/paraneoplastic CNS syndromes |
| 01. Cerebellar syndromes |
| 02. Encephalitis/encephalomyelitis (anti-NMDA, anti-IL2, limbic, other) |
| 03. Opsoclonus-myoclonus |
| 04. Epilepsy |
| 05. Other |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| Number of items: 400 (350 scored, 50 pretest) |
| Dimension 2 |
| Physician Competencies and Mechanisms |
| A. Neuroscience and mechanism of disease |
| 01. Neuroanatomy |
| a. Cerebral cortex |
| b. Connecting systems |
| c. Basal ganglia/thalamus |
| d. Brainstem |
| e. Cerebellum |
| f. Cranial nerves |
| g. Spinal cord |
| h. Spinal roots/peripheral nerves |
| i. Ventricular system, CSF |
| j. Vascular |
| k. Neuromuscular junction/muscle |
| l. Autonomic nervous system |
| m. Embryology and neural development |
| n. Pain pathways |
| o. Radiologic anatomy, cerebral blood vessels (angiography or MRA) |
| p. CSF anatomy, physiology, normal and abnormal patterns (cellular, chemical, enzymatic, serologic) |
| q. Other |
| 02. Neuropathology |
| a. Basic patterns of reaction |
| b. Cerebrovascular disease |
| c. Trauma (cranial and spinal) |
| d. Metabolic/toxic/nutritional diseases |
| e. Infections |
| f. Demyelinating diseases/leukodystrophies |
| g. Neoplasms |
| h. Congenital/developmental anomalies |
| i. Degenerative/heredodegenerative disorders |
| j. Myopathies |
| k. Peripheral nerve |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| l. Neuromuscular junction disorders |
| m. Radiologic pathology pertinent to assigned pathology sections |
| n. Other |
| 03. Neurochemistry |
| a. Carbohydrate metabolism |
| b. Lipid metabolism |
| c. Protein metabolism |
| d. Neurotransmitters |
| e. Axonal transport |
| f. Energy metabolism |
| g. Blood-brain barrier |
| h. Biochemistry of membranes/receptors/ion channels |
| i. Neuronal excitation |
| j. Vitamins (general aspects) |
| k. Inborn errors of metabolism |
| l. Electrolytes and minerals |
| m. Neurotoxins |
| n. Free radical scavengers |
| o. Excitotoxicity |
| p. Normal CSF constituents and volume |
| q. Other |
| 04. Neurophysiology |
| a. Membrane physiology |
| b. Synaptic transmission |
| c. Sensory receptors and perception |
| d. Special senses |
| e. Reflexes |
| f. Segmental and suprasegmental control of movement |
| g. Cerebellar function |
| h. Reticular system: mechanisms of sleep and arousal, consciousness, circadian rhythms |
| i. Rhinencephalon, limbic system, visceral brain |
| j. Learning and memory |
| k. Cortical organization and function |
| l. Pathophysiology of epilepsy |
| m. Cerebral blood flow |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| n. Autonomic function |
| o. Blood-brain barrier |
| p. Neurophysiology of the visual system |
| q. Neurophysiology of hearing and vestibular function |
| r. Physiology of pain |
| s. Physiology of peripheral nerve and muscle |
| t. Other |
| 05. Neuroimmunology/neuroinfectious disease |
| a. Pathogenesis of multiple sclerosis |
| b. Pathogenesis of diseases (including prion diseases) |
| c. Immunotherapy in multiple sclerosis, myasthenia gravis, and other neurologic disorders |
| d. Antibody mediated disorders |
| e. Other |
| 06. Neurogenetics/molecular neurology, and neuroepidemiology |
| a. Mendelian-inherited diseases |
| b. Other modes of inheritance |
| c. Mitochondrial disorders |
| d. Nucleotide repeat disorders |
| e. Channelopathies |
| f. Genetics of epilepsy |
| g. Risk factors in neurologic disease |
| h. Demographics of neurologic disease |
| 07. Neuroendocrinology |
| a. Thyroid gland |
| b. Cushing syndrome |
| c. Corticosteroids |
| d. Growth hormones |
| e. Hypothalamic function |
| f. Adrenal gland |
| g. Pituitary gland |
| h. Prolactin |
| i. Androgen |
| B. Clinical aspects of neurologic disease |
| 01. Epidemiology |
| 02. Risk factors |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| 03. Signs and symptoms |
| 04. Comorbidities |
| 05. Course of illness |
| 06. Prognosis |
| 07. Localization |
| 08. Pregnancy/peripartum |
| C. Diagnostic procedures |
| 01. Neuroimaging |
| a. Structural imaging (computed tomography, magnetic resonance imaging) |
| b. Vascular imaging (conventional angiography, computed tomographic angiography, magnetic resonance angiography, ultrasound) |
| c. Functional neuroimaging, including fMRI, SPECT, PET |
| 02. EEG (routine EEG, LTME, subdural and cortical EEGs) |
| 03. Magnetoencephalography |
| 04. Evoked potentials, including intraoperative monitoring |
| 05. Sleep studies, including PSG and MSLT |
| 06. EMG/NCS, including SFEMG |
| 07. Autonomic function testing |
| 08. CSF examination |
| 09. Laboratory studies |
| 10. Neuropsychological and cognitive testing |
| 11. Cardiac testing |
| 12. Tissue biopsy |
| 13. Genetic testing |
| 14. Other |
| D. Treatment/Management |
| 01. General principles of neuropharmacology |
| a. Neuropharmacokinetics/neuropharmacodynamics |
| b. Drug toxicity/side effects/idiosyncratic reactions/medication withdrawal |
| c. Drug interactions |
| d. Teratogenicity |
| e. Age, gender, and ethnicity issues |
| f. Pharmacogenomics |
| g. Mechanisms of action |
| h. Drug side effects |
| 02. Pharmacotherapy |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| a. Drugs for migraine and other headache syndromes |
| b. Analgesics (nonnarcotic, narcotic, etc.) |
| c. Anti-seizure medications |
| d. Drugs for sleep disorders |
| e. Drugs for cerebrovascular disease, including antiplatelet agents, anticoagulants, and thrombolytics |
| f. Drugs for neuromuscular disorders |
| g. Drugs for movement disorders |
| h. Drugs for multiple sclerosis (disease-modifying therapy and symptomatic treatment) |
| i. Drugs for psychiatric disorders (sedative-hypnotics, antianxiety agents, antidepressants, antipsychotics) |
| j. Vitamins/minerals/nutrients |
| k. Immunomodulatory agents, including oral medications, prednisone, IV Ig, and plasma exchange |
| l. Antimicrobial agents |
| m. Drugs used for increased intracranial pressure |
| n. Drugs for autonomic dysfunctions |
| o. Drugs for dementia |
| p. Other |
| 03. Endovascular treatment |
| 04. Neuromodulation |
| a. VNS |
| b. DBS |
| c. TENS |
| d. Spinal cord stimulation |
| e. TMS |
| f. ECT |
| 05. Critical care |
| 06. Surgical treatment |
| 07. Radiation therapy |
| 08. Rehabilitation |
| a. Exercise |
| b. Assistive devices |
| c. Assistive technologies |
| d. Braces |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|---|
| e. Physical therapy and occupational therapy |
| f. Pulmonary |
| g. Speech/swallowing |
| h. Nutrition management |
| 09. Psychotherapy, biofeedback etc. |
| 10. Reassurance, observation, no further diagnostic testing, etc. |
| 11. Specific dietary treatment |
| 12. Genetic counseling |
| 13. Other |
| E. Interpersonal and communications skills |
| 01. Communication with patients |
| 02. Communication with patients' families |
| 03. Communication with other professionals |
| 04. Communication with the healthcare team |
| 05. Communication with the public |
| 06. Management of conflict |
| 07. Common errors in communication |
| F. Professionalism |
| 01. Professional behavior |
| 02. Adherence to ethical principles (e.g., informed consent, research issues, clinical care, admission of errors) |
| 03. Participation in the professional community |
| 04. Sensitivity to diverse patient populations |
| 05. End-of-life issues and brain death |
| 06. Fatigue management |
| G. Practice-based learning and improvement |
| 01. Development and execution of lifelong learning |
| a. Self-assessment and self-improvement |
| b. Use of evidence-based guidelines |
| c. Critical review of scientific literature |
| 02. Formal practice-based quality improvement |
| H. Systems-based practice |
| 01. Patient safety and the healthcare team |
| a. Medical errors and their prevention |
| b. Communication in patient safety |



American Board of Psychiatry and Neurology, Inc.

A Member Board of the American Board of Medical Specialties (ABMS)

| |
|--|
| c. Regulatory and educational activities related to patient safety |
| 02. Resource management |
| a. Parity |
| b. Access to care |
| c. Negotiation with payers |
| 03. Community-based care |
| a. Community-based programs |
| b. Prevention |
| c. Recovery and rehabilitation |
| d. Knowledge of the legal aspects of neurological practice |
| 04. Referral for appropriate consultation/decision making |